Overview

A Study to Investigate the Safety and Efficacy of Ricolinostat

Status:
Not yet recruiting
Trial end date:
2024-04-28
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.
Treatments:
Ricolinostat